Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
35.70
-0.08 (-0.22%)
At close: Feb 27, 2026, 4:00 PM EST
35.75
+0.05 (0.14%)
After-hours: Feb 27, 2026, 7:52 PM EST
Corcept Therapeutics Revenue
In the year 2025, Corcept Therapeutics had annual revenue of $761.41M with 12.79% growth. Corcept Therapeutics had revenue of $202.13M in the quarter ending December 31, 2025, with 11.12% growth.
Revenue (ttm)
$761.41M
Revenue Growth
+12.79%
P/S Ratio
4.99
Revenue / Employee
$1,043,023
Employees
730
Market Cap
3.80B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 761.41M | 86.37M | 12.79% |
| Dec 31, 2024 | 675.04M | 192.67M | 39.94% |
| Dec 31, 2023 | 482.38M | 80.52M | 20.04% |
| Dec 31, 2022 | 401.86M | 35.88M | 9.80% |
| Dec 31, 2021 | 365.98M | 12.10M | 3.42% |
| Dec 31, 2020 | 353.87M | 47.39M | 15.46% |
| Dec 31, 2019 | 306.49M | 55.24M | 21.99% |
| Dec 31, 2018 | 251.25M | 92.05M | 57.82% |
| Dec 31, 2017 | 159.20M | 77.88M | 95.77% |
| Dec 31, 2016 | 81.32M | 31.04M | 61.72% |
| Dec 31, 2015 | 50.29M | 23.74M | 89.39% |
| Dec 31, 2014 | 26.55M | 16.19M | 156.36% |
| Dec 31, 2013 | 10.36M | 7.05M | 213.18% |
| Dec 31, 2012 | 3.31M | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | 29.00K | -180.00K | -86.12% |
| Dec 31, 2008 | 209.00K | -273.00K | -56.64% |
| Dec 31, 2007 | 482.00K | 188.00K | 63.95% |
| Dec 31, 2006 | 294.00K | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ACADIA Pharmaceuticals | 1.07B |
| Legend Biotech | 909.05M |
| ADMA Biologics | 510.17M |
| Ligand Pharmaceuticals | 268.09M |
| NewAmsterdam Pharma Company | 22.50M |
| Centessa Pharmaceuticals | 15.00M |
| Crinetics Pharmaceuticals | 7.70M |
| Xenon Pharmaceuticals | 7.50M |
CORT News
- 3 days ago - Corcept Therapeutics Incorporated (CORT) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update - Business Wire
- 8 days ago - Corcept Therapeutics: The Bad News Is Priced In; The Ovarian Cancer Upside Is Not - Seeking Alpha
- 8 days ago - Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals - Business Wire
- 9 days ago - Corcept Therapeutics Stock Plunges As Court Clears Teva Generic - Benzinga
- 10 days ago - Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call - Business Wire
- 19 days ago - CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm - GlobeNewsWire
- 19 days ago - Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT - PRNewsWire